Biogen Inc. (NASDAQ:BIIB) Q2 2024 Earnings Call Transcript
Operator: Good morning. My name is Anna and I will be your conference operator today.
Biogen Inc. (BIIB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 982,139 | $227,679,463 | +33% | 3.01% |
| 2. | OrbiMed Advisors Samuel Isaly | 900,900 | $208,846,638 | 4.12% | |
| 3. | Sarissa Capital Management Alex Denner | 643,000 | $149,060,260 | 25.16% | |
| 4. | Renaissance Technologies Jim Simons | 618,106 | $143,289,333 | -31% | 0.24% |
| 5. | Alyeska Investment Group Anand Parekh | 401,005 | $92,960,979 | +141% | 0.53% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $222.54 | 455 | Director | 20,629 | 2024-02-15 | Filing | |
| $267.00 | 898 | Director | 2,943 | 2021-02-09 | Filing | |
| $241.31 | 3,100 | Officer, Director | 34,810 | 2020-11-30 | Filing | |
| $231.24 | 38,000 | Director | 643,000 | 2019-05-02 | Filing | |
| $229.46 | 30,000 | Director | 605,000 | 2019-05-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $204.22 | 431 | Officer | 5,316 | 2024-09-03 | Filing | |
| $213.09 | 93 | Officer | 4,886 | 2024-04-02 | Filing | |
| $221.23 | 262 | Officer | 4,886 | 2024-02-22 | Filing | |
| $221.49 | 108 | Officer | 5,148 | 2024-02-16 | Filing | |
| $239.45 | 419 | Officer | 4,516 | 2024-02-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,264,481 | $4,208,759,748 | 3.33% | |
| 2. | 14,407,330 | $3,728,184,783 | 0.08% | |
| 3. | 14,246,658 | $3,686,607,689 | 0.09% | |
| 4. | 6,945,665 | $1,797,329,732 | 0.08% | |
| 5. | 5,324,396 | $1,377,793,953 | 0.25% |
News See All
Is Biogen (BIIB) an Underappreciated Stock?
Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
Biogen (BIIB) Slipped on Lower-Than-Expected Revenue Growth
ClearBridge Investments, an investment management company, released its “ClearBridge Value Equity Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here.
Morgan Stanley's Top 15 Stock Picks for 2024
In this article, we'll look into Morgan Stanley's top 15 stock picks for 2024.
10 Most Promising Stocks to Buy Before They Take Off
In this article, we discuss the 10 most promising stocks to buy before they take off.
Biogen Inc. (NASDAQ:BIIB) Q1 2024 Earnings Call Transcript
Biogen Inc. misses on earnings expectations. Reported EPS is $3.3 EPS, expectations were $3.45.
Should You Be Confident in Biogen (BIIB)?
Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” first quarter 2024 investor letter. A copy of the same can be downloaded here.
5 Best Depressed Stocks To Buy in 2024
Biogen Inc (NASDAQ:BIIB) shares are down 27% over the past one year.
5 Best S&P 500 Stocks To Buy According to Analysts
In this piece, we will take a look at the five best S&P 500 stocks to buy according to analysts.
Hedge Funds and Insiders Are Buying These 10 Stocks
In this article, we will take a detailed look at Hedge Funds and Insiders Are Buying These 10 Stocks. For a quick overview of such stocks, read our article Hedge Funds and Insiders Are Buying These...
Billionaire Hedge Funds
